Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,757 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,046)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00073398 | Vaccine Treatment for Advanced Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 54 | NewLink Genetics CorporationINDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT01380769 | A Phase 2 Study of CRLX101(NLG207) in Patients With Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 157 | NewLink Genetics CorporationINDUSTRY | 2 | May 28, 2020 | clinicaltrials |
| NCT00915005 |
| completed |
| Phase 2 |
| 275 |
| M.D. Anderson Cancer CenterOTHER |
| 1 |
| May 26, 2020 |
| clinicaltrials |
| NCT03472053 | A Study of BIO-11006 in the Treatment of Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 60 | BioMarck Pharmaceuticals, Ltd.INDUSTRY | 1 | May 19, 2020 | clinicaltrials |
| NCT00806286 | Study of Carboplatin/Paclitaxel With or Without Investigational Drug (CS-7017) in Subjects With Metastatic Non-small Cell Lung Cancer | completed | Phase 2 | 111 | Daiichi SankyoINDUSTRY | 4 | May 13, 2020 | clinicaltrials |
| NCT01671332 | Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 80 | University of Wisconsin, MadisonOTHER | 1 | May 12, 2020 | clinicaltrials |
| NCT00271505 | Avastin/Docetaxel/Carboplatin in Non-Small Cell Lung Cancer | completed | Phase 2 | 43 | M.D. Anderson Cancer CenterOTHER | 1 | May 11, 2020 | clinicaltrials |
| NCT02221739 | Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC) | completed | Phase 1 / Phase 2 | 39 | NYU Langone HealthOTHER | 1 | May 11, 2020 | clinicaltrials |
| NCT03704870 | Outcomes Following Omission of Daily Routine Chest Radiographs Following Pulmonary Resection | completed | Phase 2 | 50 | University Health Network, TorontoOTHER | 1 | May 1, 2020 | clinicaltrials |
| NCT02848651 | A Study of Atezolizumab as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer(B-F1RST) | completed | Phase 2 | 153 | Genentech, Inc.INDUSTRY | 1 | Apr 28, 2020 | clinicaltrials |
| NCT02336451 | A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges(Ascend-7) | completed | Phase 2 | 156 | Novartis PharmaceuticalsINDUSTRY | 17 | Apr 21, 2020 | clinicaltrials |
| NCT03499834 | A Study to Evaluate the Safety and Efficacy of Ex Vivo Expanded Autologous Immune Killer Cells (IKC) in Stage IV Non-small Cell Lung Cancer (NSCLC) in Patients Who Failed Chemotherapy or Target Therapy(IVY03) | completed | Phase 2 | 26 | Ivy Life Sciences, Co., LtdINDUSTRY | 1 | Apr 16, 2020 | clinicaltrials |
| NCT02573506 | Study of Split-course Chemoradiotherapy For Locally Advanced None-small Cell Lung Cancer | completed | Phase 2 | 99 | Sun Yat-sen UniversityOTHER | 1 | Apr 14, 2020 | clinicaltrials |
| NCT00137800 | Study of OSI-774 (Tarceva) in Previously Untreated Elderly Lung Cancer Patients | completed | Phase 2 | 82 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 3, 2020 | clinicaltrials |
| NCT01773109 | Etirinotecan Pegol (NKTR-102) in NSCLC | completed | Phase 2 | 40 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 3, 2020 | clinicaltrials |
| NCT02544633 | Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET | completed | Phase 2 | 68 | Mirati Therapeutics Inc.INDUSTRY | 9 | Mar 4, 2020 | clinicaltrials |
| NCT03652857 | Apatinib Combined With Vinorelbine for Non-driver Gene Mutation Non-small Cell Lung Cancer | completed | Phase 2 | 30 | Yongchang ZhangOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT02590965 | A Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer | completed | Phase 2 | 91 | Hutchison Medipharma LimitedINDUSTRY | 1 | Feb 13, 2020 | clinicaltrials |
| NCT03155009 | A Study of the Efficacy and Safety of Alectinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer(ATALK) | completed | Phase 2 | 44 | Hoffmann-La RocheINDUSTRY | 1 | Feb 10, 2020 | clinicaltrials |
| NCT01933347 | Third-line Treatment of Gefitinib in NSCLC Patients | completed | Phase 2 | 46 | Guangdong Association of Clinical TrialsOTHER | 1 | Feb 6, 2020 | clinicaltrials |
| NCT01065441 | Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer | completed | Phase 1 / Phase 2 | 9 | Michael Har-NoyINDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT01310244 | MTD Study PXD-101 in Combination With Paclitaxel + Carboplatin in Chemotherapy-Naive Patients With Stage IV NSCLC | completed | Phase 1 / Phase 2 | 23 | Acrotech Biopharma Inc.INDUSTRY | 1 | Jan 6, 2020 | clinicaltrials |
| NCT02031458 | A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer(BIRCH) | completed | Phase 2 | 667 | Hoffmann-La RocheINDUSTRY | 19 | Jan 6, 2020 | clinicaltrials |
| NCT00290355 | Study to Test the Efficacy of the Vaccine GSK 249553 in Treating Non-small-cell Lung Cancer After Tumour Removal by Surgery | completed | Phase 2 | 182 | GlaxoSmithKlineINDUSTRY | 14 | Jan 2, 2020 | clinicaltrials |
| NCT01880528 | Lisinopril in Reducing Shortness of Breath Caused by Radiation Therapy in Patients With Lung Cancer | completed | Phase 2 | 23 | Mayo ClinicOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT00200395 | OSI-774 (Erlotinib, Tarceva) in Elderly Patients | completed | Phase 2 | 30 | Montefiore Medical CenterOTHER | 1 | Dec 30, 2019 | clinicaltrials |
| NCT02047344 | Efficacy, Safety and Pharmacokinetics Study of Antroquinonol to Treat NSCLC | completed | Phase 2 | 31 | Golden Biotechnology CorporationINDUSTRY | 2 | Dec 26, 2019 | clinicaltrials |
| NCT01813734 | Ponatinib in Advanced NSCLC w/ RET Translocations | completed | Phase 2 | 9 | Massachusetts General HospitalOTHER | 1 | Dec 24, 2019 | clinicaltrials |
| NCT00137839 | Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung | completed | Phase 2 | 84 | Pasi A. Janne, MD, PhDOTHER | 1 | Dec 17, 2019 | clinicaltrials |
| NCT00798720 | Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung Cancer | completed | Phase 2 | 18 | University of Wisconsin, MadisonOTHER | 0 | Dec 13, 2019 | clinicaltrials |
| NCT03129256 | An Exploration of Apatinib Combined With S-1 in Patients With Advanced Non-small Cell Lung Cancer(EASE) | completed | Phase 2 | 52 | Changzhou Cancer Hospital of Soochow UniversityOTHER | 1 | Dec 10, 2019 | clinicaltrials |
| NCT00563784 | TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 68 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 20, 2019 | clinicaltrials |
| NCT03023423 | A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer(DARZALEX) | completed | Phase 1 / Phase 2 | 100 | Janssen Research & Development, LLCINDUSTRY | 5 | Nov 20, 2019 | clinicaltrials |
| NCT00582634 | Adjuvant Cisplatin and Docetaxel in Non Small Cell Lung Cancer | completed | Phase 2 | 4 | University of Wisconsin, MadisonOTHER | 1 | Nov 19, 2019 | clinicaltrials |
| NCT02976116 | A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer | completed | Phase 2 | 50 | Hutchison Medipharma LimitedINDUSTRY | 1 | Nov 15, 2019 | clinicaltrials |
| NCT00274443 | An Open Label Study in Patients With Advanced NSCLC With ABI-007(Abraxane) in Combination With Carboplatin | completed | Phase 2 | 250 | CelgeneINDUSTRY | 1 | Nov 12, 2019 | clinicaltrials |
| NCT01631357 | Study of Chemotherapy Combination With Autologous Cytokine-Induced Killer Cell Immunotherapy to Treat Lung Cancer(CIK) | completed | Phase 2 / Phase 3 | 96 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 5, 2019 | clinicaltrials |
| NCT00771953 | 0822GCC: Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer | completed | Phase 2 | 109 | University of Maryland, BaltimoreOTHER | 1 | Oct 30, 2019 | clinicaltrials |
| NCT00647426 | Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC | completed | Phase 2 | 7 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Oct 22, 2019 | clinicaltrials |
| NCT03544814 | EGFR-TKI Combined With Concurrent or Sequential Chemotherapy for Patients of Gradual Progression | completed | Phase 2 | 99 | Shanghai Chest HospitalOTHER | 0 | Oct 15, 2019 | clinicaltrials |
| NCT01806675 | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy | completed | Phase 1 / Phase 2 | 25 | Sanjiv Sam GambhirOTHER | 1 | Oct 3, 2019 | clinicaltrials |
| NCT01165021 | A Study of Pemetrexed/Cisplatin as Pre-operative Treatment of Early Stage Nonsquamous Non-Small Cell Lung Cancer | completed | Phase 2 | 19 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 25, 2019 | clinicaltrials |
| NCT00775307 | Adjuvant Pazopanib in Stage I NSCLC | completed | Phase 2 / Phase 3 | 142 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Sep 24, 2019 | clinicaltrials |
| NCT01281124 | Azacitidine in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer | completed | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 1 | Sep 24, 2019 | clinicaltrials |
| NCT01232452 | A Study in Non-Small Cell Lung Cancer | completed | Phase 2 | 172 | Eli Lilly and CompanyINDUSTRY | 12 | Sep 20, 2019 | clinicaltrials |
| NCT00349089 | Trial on Refinement of Early Stage Lung Cancer Adjuvant Therapy | completed | Phase 2 | 132 | Thoraxklinik-Heidelberg gGmbHOTHER | 3 | Sep 19, 2019 | clinicaltrials |
| NCT01059643 | A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 103 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 18, 2019 | clinicaltrials |
| NCT01900652 | A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants(Chime) | completed | Phase 2 | 111 | Eli Lilly and CompanyINDUSTRY | 10 | Sep 18, 2019 | clinicaltrials |
Data updated 23 days agoSource updated May 28, 2020source: clinicaltrials